Immunocodex is a company headquartered in the United States.
Immunocodex develops tolerogenic mRNA vaccines designed to reprogram immune cells and restore immune balance for the treatment of autoimmune diseases.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.